Indication · Neurology & Neurosurgery
Hydrocephalus
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
223
Cleared or approved since 2000
PMA and De Novo
1
Higher-risk or first-of-kind devices
Breakthrough devices
0
Authorized through June 30, 2026
Recruiting device trials
12
83 device trials in all
Devices
1 devices via De Novo. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- Medtronic DUET External Drainage and Monitoring System
Medtronic Neurosurgery · De Novo · External Cerebrospinal Fluid (Csf) Diversion · newest 2014
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
Rhaeos, Inc.Not on our public-company list
NCT07815314 · 85 participants (planned) · Start Sep 23, 2026 · Primary completion Jan 2027
Device: Rhaeos Shunt Monitoring System (RSMS); ShuntCheck III · For: Hydrocephalus
Sites: Chicago, Illinois; Baltimore, Maryland; Williamsville, New York · 4 sites in all
82 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Shunt, Central Nervous System And Components (JXG)108
- Device, Monitoring, Intracranial Pressure (GWM)56
- Endoscope, Neurological (GWG)45
- Catheter, Ventricular (HCA)7
- Catheter, Ventricular (Containing Antibiotic Or Antimicrobial Agents) (NHC)3
- Cannula, Ventricular (HCD)2
- External Cerebrospinal Fluid (Csf) Diversion (PCB)2
Research
- Device studies on hydrocephalus across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.